Auxilium Health, a Cleveland, Ohio-based developer of smart biomaterials, has raised $3.4 million in seed funding led by Cottington Investments. The company’s Aer™ platform engineers bioaerogels that mimic the body’s extracellular matrix to resist bacterial attachment while promoting tissue regeneration without antibiotics. The capital will advance the lead product Aux-Shield toward FDA clearance and first-in-human studies.
Bioaerogels Address Antibiotic-Free Wound Needs
The timing aligns with accelerating demand for non-antibiotic infection solutions. Competitors such as Dimension Inx secured $12 million Series A in 2023, while RevBio has raised over $42 million total. Auxilium’s structural approach to winning the “race for the surface” differentiates it from post-colonization anti-biofilm strategies.
Chronic Wounds Cost U.S. Healthcare $50 Billion
More than 6.5 million patients in the U.S. suffer from non-healing wounds, generating over $50 billion in annual healthcare costs. Diabetic foot ulcers represent the initial target. Existing dressings either rely on antibiotics, risking resistance, or focus solely on regeneration without addressing bacterial colonization at the material surface.
Aer Platform Structurally Wins Healing Race
Auxilium’s Aer™ bioaerogel is engineered to prevent bacterial attachment from the outset while recruiting regenerative cells. This dual therapeutic-diagnostic capability contrasts with peptide membranes from Gel4Med or amniotic products from BioTissue that either kill bacteria after arrival or depend on donor tissue supply chains.
As Isaiah Kaiser, PhD, Founder and CEO noted:
"In biomaterials science, regenerative cells and bacteria race to control a material’s surface during healing. For years, approaches have only considered one side of that race. At Auxilium, we’re rigging the race with a new class of bio-selective materials so patients won’t have to fear the outcome, but can have hope."
Cottington Leads Oversubscribed Round
Cottington Investments anchored the round with participation from StatePark Capital, VentureWell, Freshwater Angels, and Pointe Angels. The oversubscribed seed round more than doubles the company’s prior $1.5 million pre-seed raise and signals growing conviction in its University of Akron-licensed polymer technology now headquartered at Cleveland Clinic’s Global Innovation Center.
Biomaterial Wound Market Grows at 8.2% CAGR
The biomaterial wound dressing market is projected to expand from $7.6 billion in 2026 to $13.1 billion by 2033. Parallel segments such as anti-biofilm dressings are growing at 11.1% CAGR. Rising antimicrobial resistance and the shift toward bioactive, ECM-mimicking materials are drawing capital into platforms that combine infection resistance with regeneration.
Competitors including CollPlant Biotechnologies raised $2.6 million in June 2026, while Dimension Inx and RevBio demonstrate sustained investor interest in regenerative biomaterials.